Corvus Pharmaceuticals (CRVS) Free Cash Flow (2022 - 2025)
Historic Free Cash Flow for Corvus Pharmaceuticals (CRVS) over the last 4 years, with Q3 2025 value amounting to -$9.6 million.
- Corvus Pharmaceuticals' Free Cash Flow fell 5133.68% to -$9.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$32.2 million, marking a year-over-year decrease of 4562.05%. This contributed to the annual value of -$25.4 million for FY2024, which is 607.03% down from last year.
- Per Corvus Pharmaceuticals' latest filing, its Free Cash Flow stood at -$9.6 million for Q3 2025, which was down 5133.68% from -$5.9 million recorded in Q2 2025.
- In the past 5 years, Corvus Pharmaceuticals' Free Cash Flow ranged from a high of -$5.2 million in Q1 2024 and a low of -$9.6 million during Q3 2025
- In the last 4 years, Corvus Pharmaceuticals' Free Cash Flow had a median value of -$6.3 million in 2024 and averaged -$6.7 million.
- Over the last 5 years, Corvus Pharmaceuticals' Free Cash Flow had its largest YoY gain of 3668.51% in 2024, and its largest YoY loss of 6382.81% in 2024.
- Over the past 4 years, Corvus Pharmaceuticals' Free Cash Flow (Quarter) stood at -$7.5 million in 2022, then surged by 31.54% to -$5.2 million in 2023, then plummeted by 63.83% to -$8.5 million in 2024, then fell by 13.01% to -$9.6 million in 2025.
- Its Free Cash Flow was -$9.6 million in Q3 2025, compared to -$5.9 million in Q2 2025 and -$8.3 million in Q1 2025.